Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA^® registry

References

• Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011; 117:7121–7125.
   PubMed Web of Science ®Google Scholar
• Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:287–294.
   PubMed Web of Science ®Google Scholar
• Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513–1522.
   PubMed Web of Science ®Google Scholar
• Balducci L. Transfusion independence in patients with myelodysplastic syndromes:impact on outcomes and quality of life. Cancer 2006;106:2087–2094.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850–1856.
   PubMed Web of Science ®Google Scholar
• Vidaza® prescribing information. Summit, NJ: Celgene Corporation; 2011. [Revised August 2011]
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Maringwa J, Quinten C, King M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011;22:2107–2112.
   PubMed Web of Science ®Google Scholar
• Pashos CL, Grinblatt DL, Sekeres MA, et al. Association of changes in transfusion status with changes in health-related quality of life of real-world patients with MDS across six months of treatment with azacitidine. Blood 2011;118(Suppl. 1): Abstract 2796.
   Google Scholar
• Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010;85:130–138.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes:results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542–1551.
   PubMed Web of Science ®Google Scholar
• Sekeres MA. How to manage lower-risk myelodysplastic syndromes. Leukemia 2012;26:390–394.
   PubMed Web of Science ®Google Scholar
• Lindquist KJ, Danese MD, Mikhael J, et al. Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol 2011;22:1181–1188.
   PubMed Web of Science ®Google Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007;31(Suppl. 3):S2–S6.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Hong F, Bosco JL, Bush N, et al. Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy. BMC Cancer 2013;13:165.
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle H, Birgegard G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/ = 120 g/L with darbepoetin alfa +/2 filgrastim or erythrocyte transfusions. Eur J Haematol 2011;87:244–252.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:459–468.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433–1440.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brandenburg NA, Muus P, et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res 2013;37:259–265.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor:significant effects on quality of life. Br J Haematol 2003;120:1037–1046.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome:studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7(Suppl. 1):21–29.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29:2521–2527.
   PubMed Web of Science ®Google Scholar